AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02625558
Drug: Riociguat
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day
Trial: NCT00706134
Drug: Aliskiren 75 mg
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
Trial: NCT00706134
Drug: Aliskiren 150 mg
RxNorm normalized name: aliskiren 150 MG
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
Trial: NCT00706134
Drug: Aliskiren 300 mg
RxNorm normalized name: aliskiren 300 MG
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg tablet taken once daily in the morning with a light meal.
Trial: NCT01372904
Drug: Dexamethasone Phosphate
RxNorm normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.7ml of Dexamethasone Phosphate 10mg/ml would be injected unilaterally to the middle ear using 25 gauge spinal needle.~The trans-tympanic membrane injection would take place at the posterior inferior quadrant of the ear drum facing the round window niche. The patient would be instructed to lie down for 20 minutes after the injection with the treated side up and to avoid swallowing or coughing. Intratympanic Dexamethasone would be delivered immediately prior to each cisplatin treatment as maximal level.
Trial: NCT01339559
Drug: Brivaracetam
RxNorm normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet, Flexible dosing up to 200 mg/day, twice daily.~The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor.
Trial: NCT00971945
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution, I.V., 100 mg/m2, Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
Trial: NCT03691974
Drug: Fasinumab
RxNorm normalized name: Fasinumab
DrugBank: Fasinumab (DB12157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) every four weeks (Q4W)
Trial: NCT03193203
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 mg/mL PFS and AI
Trial: NCT03557099
Drug: Hetrombopag Olamine
RxNorm normalized name: Eltrombopag Olamine
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT03989310
Drug: Manganese Chloride
RxNorm normalized name: Manganese Chloride
DrugBank: Manganese citrate (DB14495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by inhalation at 0.4mg/kg twice per week in a 3-week cycle
Trial: NCT03989310
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously, 200mg/d on day 1 and day 8 in a 3-week cycle
Trial: NCT03989310
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
Trial: NCT03989310
Drug: anti-PD-1 antibody
RxNorm normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously, 2-4mg/kg on day 2 in a 3-week cycle
Trial: NCT02764970
Drug: Ivabradine 7.5mg orally
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: additive use to the standard medication with bisoprolol
Trial: NCT02587052
Drug: Generic tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic tacrolimus
Trial: NCT02587052
Drug: Prograf
RxNorm normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prograf, the original tacrolimus
Trial: NCT03316690
Drug: Metformin treatment
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily treatment with metformin tablets for 101 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-101: Metformin tablet 1000 mg x 2
Trial: NCT00328536
Drug: Omacor
RxNorm normalized name: Omacor
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02795143
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00274456
Drug: ABI-007
RxNorm normalized name: ABI-007 COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m\^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.
Trial: NCT00274456
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel dosed q3w at 100 mg/m\^2
Trial: NCT00121875
Drug: somatropin (rDNA)
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Form/Strength: 10 mg aqueous suspension; 5 mg/ml~Dosage/Frequency: 0.35 mg/kg/week, daily divided doses~Duration: 6 months with 3-month washout period
Trial: NCT03954860
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) is an anti-fibrinolytic drugcan，which can increase the stability of fibrin clots and achieve hemostasis for High tibial osteotomy'patients.
Trial: NCT03954860
Drug: Sodium Chloride 0.9%
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 0.9% is a solution of sodium chloride, which has the same osmotic pressure as animal or human plasma in physiological experiments or clinics, and can be used to dilute Tranexamic Acid .
Trial: NCT02670642
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor
Trial: NCT01535781
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g of tranexamic acid as a bolus immediately before surgery 3 g of tranexamic acid in 24hours postop.
Trial: NCT00691483
Drug: varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: varenicline tablets, 1 mg taken orally twice daily for 12 weeks
Trial: NCT00746252
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Children will have a flexible dose titration based on their unique response to the medication (assessed using clinical global improvement scores). Children will be treated for six months using daily, bid dosing.
Trial: NCT00746252
Drug: aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: children will have a flexible dosing titration based on their unique response (assessed using clinical global improvement scores). Children will be treated with daily medication for six months.
Trial: NCT04295161
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate immediate release formulations
Trial: NCT00604968
Drug: Caelyx (pegylated liposomal doxorubicin; SCH 200746)
RxNorm normalized name: Caelyx
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caelyx will be administered intravenously at a dose of 40 mg/m\^2 on day one every 4 weeks until progression, or unacceptable toxicity, or other reason to discontinue the study treatment. The drug is diluted in 250 ml glucose 5% (500 ml for doses \>=90 mg).
Trial: NCT03231176
Drug: Varlitinib
RxNorm normalized name: Varlitinib
DrugBank: Varlitinib (DB05944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets, twice daily
Trial: NCT01494363
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85 mg/m2 (diluted in 250 ml of 5% dextrose solution) given as a 2-hour intravenous infusion every 2 weeks
Trial: NCT01494363
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 150 mg/m2 (diluted in 250 ml of 0.9% normal saline solution) given as a 90-minute intravenous infusion every 2 weeks
Trial: NCT00578643
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -9 through -6~1 mg/kg initially (based on weight)
Trial: NCT02560532
Drug: Clazosentan
RxNorm normalized name: clazosentan
DrugBank: Clazosentan (DB06677)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Concentrated solution for intravenous injection
Trial: NCT01737697
Drug: Zirconium silicate (acute phase)
RxNorm normalized name: silicic acid
DrugBank: Silicic acid (DB14138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
Trial: NCT00049673
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00049673
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT03927105
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab is a human monoclonal antibody (HuMAb; immunoglobulin G4 \[IgG4\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.1 Binding of PD-1 to its ligands, programmed death-ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T-cell responses to both foreign antigens as well as self-antigens. Nivolumab will be delivered intravenously at a fixed dose of 240 mg on day 1 of 14 day cycles.
Trial: NCT03927105
Drug: cabiralizumab
RxNorm normalized name: Cabiralizumab
DrugBank: Cabiralizumab (DB15082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabiralizumab is a recombinant, humanized Immunoglobulin G4 (IgG4) monoclonal antibody that binds to human colony stimulating factor 1 receptor (CSF1R; c-fms). Cabiralizumab will be delivered intravenously at a dosage of 4 mg/kg on day 1 of 14 day cycles.
Trial: NCT00578643
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -5 through Day -2~30 mg/m\^2
Trial: NCT00578643
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine will be administered beginning Day -2. Initial dose will 5 mg/kg infused over 24 hours.
Trial: NCT00242294
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02613455
Drug: Kenalog (triamcinolone)
RxNorm normalized name: triamcinolone Injection [Kenalog]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
Trial: NCT02613455
Drug: lidocaine 1% (lidocaine HCl 20mg)
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
Trial: NCT01436539
Drug: Adefovir Dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir Dipivoxil 10 mg once daily for 48 weeks
Trial: NCT00317798
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: escalating doses of rATG, intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
Trial: NCT04340843
Drug: Belinostat
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00090103
Drug: dutasteride 0.5mg once daily for 4 years
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: combination or single agent
Trial: NCT01421901
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertapenem i.v,m 1g, once a day, 3 days
Trial: NCT01768455
Drug: Gemigliptin and Glimepiride
RxNorm normalized name: glimepiride and pioglitazone
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemigliptin 50mg (qd) on Day1\~Day6 and Gemigliptin 50mg (qd) and Glimepiride 4mg (qd) on Day7
Trial: NCT01768455
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride 4mg (qd) on Day1
Trial: NCT00976066
Drug: Part A Assessing GSK1521498
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive up to three \[11C\]carfentanil PET scans and up to two doses of GSK1521498 in total. The doses used will span the expected receptor occupancy range providing these were well tolerated in the first-time in human study.~Each subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively), followed by two treatment sessions (Treatment Sessions 1 and 2). Treatment session 1 and 2 are followed by PET scans and an fMRI scan (session 1 only). Sessions will be separated by at least 12 days. PET scans will be timed to coincide with peak brain occupancy. fMRI will begin approximately 30-60 minutes after completion of the PET scan.
Trial: NCT00976066
Drug: Part B Assessing GSK1521498
RxNorm normalized name: SODIUM CHLORITE 0.0256 kg in 1 kg TOPICAL SPRAY [Chlorsan 105 Part B]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The purpose of Part B is to establish the timecourse of receptor occupancy of GSK1521498. Each participant in Part B will receive up to three \[11C\]carfentanil PET scans and one single oral dose of GSK1521498 expected to provide 50-75% receptor occupancy (selected with reference to data from Part A).~Each Part B subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of GSK1521498 followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
Trial: NCT00976066
Drug: Part C Assessing Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A range of doses of naltrexone will be tested in up to 12 participants in an adaptive design. Each Part C participant will receive up to three \[11C\]carfentanil PET scans and a single oral dose of naltrexone. No dose of naltrexone will exceed 50 mg, the dose usually used therapeutically in the treatment of opiate and alcohol dependence. Each Part C subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of naltrexone followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
Trial: NCT00656786
Drug: Menadione Topical Lotion
RxNorm normalized name: Menadione
DrugBank: Menadione (DB00170)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Menadione Lotion will be applied topically twice a day; beginning when the rash appears during EGFRi therapy.
Trial: NCT00656786
Drug: Menadione Topical Lotion
RxNorm normalized name: Menadione
DrugBank: Menadione (DB00170)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Menadione Lotion will be applied topically twice a day, starting 1 day before EGFRi therapy.
Trial: NCT00090103
Drug: tamsulosin 0.4mg once daily for 4 years
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: combination agent or single agent
Trial: NCT03566329
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulphate 50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion. .
Trial: NCT03566329
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine hydrochloride 1.5mg/kg loading followed by 2mg/kg/hr infusion
Trial: NCT01737697
Drug: Zirconium silicate (subacute phase)
RxNorm normalized name: silicic acid
DrugBank: Silicic acid (DB14138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
Trial: NCT04729868
Drug: Levobupivacaine(chirocaine) plus dexmedetomidine(precedex)
RxNorm normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries
Trial: NCT00003997
Drug: irofulven
RxNorm normalized name: Irofulven
DrugBank: Irofulven (DB05786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04340843
Drug: Guadecitabine
RxNorm normalized name: Guadecitabine
DrugBank: Guadecitabine (DB11918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT04693000
Drug: Arsenic Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment
RxNorm normalized name: scabies lesion lysate (human)
DrugBank: Solasodine (DB18813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.Keratotic nodular size observation after 12 weeks
Trial: NCT00598052
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/day
Trial: NCT00687518
Drug: Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 50 U/kg of erythropoietin
Trial: NCT04865705
Drug: tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilelizumab 200mg d1 Q3W Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1 every 3 weeks
Trial: NCT01871454
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pentoxifylline
Trial: NCT02025426
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02025426
Drug: Ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00596375
Drug: Lidocaine Lubricant
RxNorm normalized name: Eyes Alive Lubricating
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% Lidocaine lubricant instillation prior to urethral catheterization
Trial: NCT04273178
Drug: Escalating prophylaxis
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the prophylaxis treatment will be extended until recovery of aGVHD and tapering of immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to d+100 and anti-mold prophylaxis will be given in case of active aGVHD.
Trial: NCT01916265
Drug: Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00034372
Drug: oregovomab
RxNorm normalized name: Oregovomab
DrugBank: Oregovomab (DB04964)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01262365
Drug: Epratuzumab
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles